Free Trial
NASDAQ:RENB

Renovaro (RENB) Stock Price, News & Analysis

Renovaro logo
$0.53
-0.01 (-1.84%)
(As of 10/31/2024 ET)

About Renovaro Stock (NASDAQ:RENB)

Key Stats

Today's Range
$0.53
$0.60
50-Day Range
$0.41
$0.93
52-Week Range
$0.40
$5.25
Volume
174,091 shs
Average Volume
551,820 shs
Market Capitalization
$78.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Renovaro Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
36th Percentile Overall Score

RENB MarketRank™: 

Renovaro scored higher than 36% of companies evaluated by MarketBeat, and ranked 800th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Renovaro is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Renovaro is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Renovaro has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Renovaro's valuation and earnings.
  • Percentage of Shares Shorted

    3.75% of the float of Renovaro has been sold short.
  • Short Interest Ratio / Days to Cover

    Renovaro has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Renovaro has recently decreased by 7.41%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Renovaro does not currently pay a dividend.

  • Dividend Growth

    Renovaro does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.75% of the float of Renovaro has been sold short.
  • Short Interest Ratio / Days to Cover

    Renovaro has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Renovaro has recently decreased by 7.41%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Renovaro has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Renovaro this week, compared to 1 article on an average week.
  • MarketBeat Follows

    2 people have added Renovaro to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Renovaro insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.72% of the stock of Renovaro is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    71.41% of the stock of Renovaro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Renovaro's insider trading history.
Receive RENB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renovaro and its competitors with MarketBeat's FREE daily newsletter.

RENB Stock News Headlines

Renovaro BioSciences files $200M mixed securities shelf
Renovaro (NASDAQ:RENB) Stock Price Down 4% - Time to Sell?
Watch this before it gets removed
If you missed it, my emergency election broadcast is now available - but will be removed soon
See More Headlines

RENB Stock Analysis - Frequently Asked Questions

Renovaro's stock was trading at $3.17 at the beginning of the year. Since then, RENB shares have decreased by 83.2% and is now trading at $0.5321.
View the best growth stocks for 2024 here
.

Renovaro Inc. (NASDAQ:RENB) released its quarterly earnings data on Thursday, October, 10th. The company reported ($0.45) earnings per share for the quarter.

Shares of RENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Renovaro investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

Last Earnings
10/10/2024
Today
10/31/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RENB
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-80,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.89 per share

Miscellaneous

Free Float
122,269,000
Market Cap
$78.49 million
Optionable
Optionable
Beta
0.56
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:RENB) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners